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Background: The snakes from the Bitis genus are some of the most medically important venomous snakes in sub
Saharan Africa, however little is known about the composition and effects of these snake venom peptides.
Considering that the victims with Bitis genus snakes have exacerbate hypotension and cardiovascular disorders,
we investigated here the presence of angiotensin-converting enzyme modulators on four different species of
venoms.
Methods: The peptide fractions from Bitis gabonica gabonica, Bitis nasicornis, Bitis gabonica rhinoceros and
Bitis arietans which showed inhibitory activity on angiotensin-converting enzyme were subjected to mass
spectrometry analysis. Eight proline-rich peptides were synthetized and their potencies were evaluated
in vitro and in vivo.
Results: TheMS analysis resulted in over 150 sequences, out of which 32 are new proline-rich oligopeptides, and
eight were selected for syntheses. For some peptides, inhibition assays showed inhibitory potentials of cleavage
of angiotensin I ten times greater when compared to bradykinin. In vivo tests showed that all peptides decreased
mean arterial pressure, followed by tachycardia in 6 out of 8 of the tests.
Conclusion: We describe here some new and already known proline-rich peptides, also known as bradykinin-
potentiating peptides. Four synthetic peptides indicated a preferential inhibition of angiotensin-converting
enzyme C-domain. In vivo studies show that the proline-rich oligopeptides are hypotensive molecules.
General signiﬁcance: Although proline-rich oligopeptides are known molecules, we present here 32 new
sequences that are inhibitors of the angiotensin-converting enzyme and consistent with the symptoms of the
victims of Bitis spp, who display severe hypotension.© 2015 Elsevier B.V. All rights reserved.1. Introduction
In sub-Saharan Africa, snakebite envenomation is considered a highly
relevant public health hazard, of great importance in relation tomortality
and morbidity. Although data on incidence and mortality from snake-
bites in Africa are underestimated, recent reports showed that snakebites
represent an important but neglected public health problem among poor
rural populations. It has been estimated that a half million snakebitesry, Butantan Institute, Av. Prof.
zil. Tel.: +55 11 2627 9716;
V. Portaro).occur every year in Africa, mainly in sub-Saharan Africa, resulting in
100,000 to 500,000 poisonings and 3500 to 32,000 deaths [1].
Snakes belonging to the genus Bitis, from the Viperidae family, are
implicated inmany accidentswith humans and are consideredmedical-
ly important vipers. According to theWHO [2], accidents caused by Bitis
arietans (BA), also known as puff adder, are themost frequent in Africa.
Envenomation from these animals results in intense local damage, coag-
ulopathy, thrombocytopenia, spontaneous local bleeding and hypoten-
sion [3,4]. Envenomation by B. arietans can be extensive and advanced
necrosis may require partial or total amputation of the bitten limb,
being even fatal in some cases [2]. Bitis gabonica gabonica (BG), Bitis
gabonica rhinoceros (BR) and Bitis nasicornis (BN), also known as
Gaboon vipers, are responsible for most accidents in southern Nigeria
and some of these cases can lead victims to systemic symptoms, such
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in turn can lead to life-threatening envenomation. Despite the high
toxicity, fortunately there are not many reported cases of accidents
with these snakes in sub-Saharan Africa, and also local effects seen in
envenoming cases with Gaboon vipers are less severe than those
observed in accidents with BA [2].
Functional evaluations about these venoms demonstrated the
presence of peptidases (metallo and serine) [6–8], phospholipases A2
[9], C-type lectins and hyaluronidase activities [10]. Proteomic analyses
showed thatmetallopeptidases, serine peptidases, disintegrins, L-amino
acid oxidase, Kunitz inhibitors, phospholipases A2, cystatins and C-type
lectins are present in all Bitis venoms studied [11–13]. Interestingly,
only the proteomic analysis of the venom of BG and BR demonstrated
the presence of proline-rich oligopeptides (PROs), also known as
bradykinin-potentiating peptides (BPPs) [11,12]. Since not all pep-
tides known as BPPs are able to potentiate the effects of bradykinin,
although they show inhibition of ACE, they are currently referred to
as PROs [14].
The proline-rich oligopeptides present in the Bothrops jararaca
venom (Bj-PROs) were the ﬁrst naturally occurring angiotensin-
converting enzyme (ACE, EC 3.4.15.1) inhibitors described [15]. One of
them, the BPP-Va, (bEKWAP, bE=pyroglutamyl residue), is amolecule
that originally inspired the design of current commercial inhibitors of
ACE [16]. To date, they have also been considered the most potent nat-
ural ACE inhibitors and, with few exceptions, they all share the same
characteristics, including: 1) a pyroglutamyl residue at the N-terminal;
2) a high content of proline residues and 3) the tripeptide Ile-Pro-Pro
at the C-terminus.
The somatic angiotensin-converting enzyme (ACE) is a dipeptidyl
carboxypeptidase present on the external surface of endothelial cells.
This enzyme, which plays a central role in blood pressure regulation,
is composed of two highly similar domains (referred to as the N- and
C- domains), each containing an active site, characterized by the
presence of a zinc-metallopeptidase HEXXH consensus motif (for re-
view see [17]). In fact, the action of ACE toward circulating vasoactive
peptides increases blood pressure by generating angiotensin II (Ang II,
Pro-hypertensive octapeptide) and by inactivating bradykinin (BK,
hypotensive peptide). The C-domain of mammalian ACE is mainly re-
sponsible for Ang II formation while bradykinin is inactivated by both
domains with the same efﬁciency [18]. In fact, some of the proline-
rich oligopeptides from snake venoms display selective potency toward
the C-domain of ACE [19,20]. Thus, these peptides produce a hypoten-
sive effect in vivo by inhibiting the ACE activity [20], however, other
targets that can also induce the cardiovascular effects of different PROs
are not exclusively due to the inhibition of ACE [21].
Considering that the victims of accidents with snakes of the genus
Bitis have exacerbated hypotension and cardiovascular disorders, we
investigated the presence of ACE modulators and found a set of new
PROs in the fraction of low molecular mass of these venoms, as well as
two sequences already described in the venom of B. jararaca. The selec-
tive ACE domains binded by eight synthetic proline-rich oligopeptides
were studied using Ang I and BK as substrates. The in vivo assays were
performed to evaluate the physiological effects of these molecules,
and to correlate them with the in vitro results.
2. Experimental procedures
2.1. Materials
The lyophilized crude venomof B. arietans, B. gabonica, B. g. rhinoceros
and B. nasicornis were purchased from Latoxan SAS (Vallence, France).
Rabbit lung somatic ACE-I, human angiotensin I and human bradykinin
were obtained from Sigma-Aldrich (St Louis, MO, USA). The ACE
substrate Abz-FRK(2,4-dinitrophenol)P-OH was kindly provided by Dr.
Adriana Carmona (Department of Biophysics, UNIFESP-EPM, São
Paulo, Brazil). The synthetic PROs were purchased from GenOneBiotechnologies (Rio de Janeiro, Brazil). The purity of all peptides
was analyzed by reverse-phase HPLC and the primary sequences
were conﬁrmed by analysis of MS/MS. Acetonitrile acid and
triﬂuoroacetic acid (TFA) were obtained from J.T. Baker.
2.2. Animals
Experiments were performed 43 in adult maleWistar rats weighing
250–280 g. Experimental protocols were approved by the Animal
Experimentation Ethics Committee of the Institute of Biomedical Science
at the University of São Paulo (ICB/USP). The animals had free access to
water and food, and were kept under a 12 h light–dark cycle. All proce-
dures involving animals and their care were conducted in accordance
with the Guidelines for the Use of Animals in Biochemical Research.
2.3. Obtainment of the peptide fractions of poisons and HPLC fractionation
Lyophilized venoms of BA (10.6 mg), BG (9.6 mg), BR (9.5 mg) and
BN (9.4 mg) were dissolved in 0.05 M ammonium acetate pH 4.2 in a
ﬁnal volume of 5.0 mL, and immediately ﬁltered through a Merck
Millipore Amicon Ultracel 10 K centrifugalﬁlter devicewith amolecular
mass cut-off of 10,000 Da (Tullagreen, Carrigtwohill, IRL), in order to
prevent proteolytic cleavage of peptides by the crude venom. Filtrated
solutions containing low molecular mass fractions were injected
(500 μL) in a reverse-phase HPLC (Prominence, Shimadzu, Japan),
using 0.1% triﬂuoroacetic acid (TFA) in water, as solvent A, and acetoni-
trile and solvent A (9:1) as solvent B. The separations were performed
at a ﬂow rate of 1 mL/min using a Restek Ultra C-18 column
(4.6 × 150 mm) and a 20–60% gradient of solvent B over 20 min. In all
cases, elution was followed by the measurement of ultraviolet
absorption (214 nm). The peaks were manually collected, dried and
subjected to enzymatic assays.
2.4. Searching for ACE inhibitors
The enzymatic activity assays of ACE were conducted in a 100 mM
Tris, 50 mM NaCl, 10 μM ZnCl2 buffer, pH 7.0, using the FRET substrate
Abz-FRK(Dnp)P-OH at the concentration of 4 μM, at 37 °C. The reaction
was initiated by the addition of ACE (50 ng). The ACE peptidase inhibi-
tion assays were performed using 20 μL of each collected peak of the
venoms fractionations described above. All reactions were monitored
in a continuous assay by measuring hydrolysis using a ﬂuorimeter
(Victor 3™, Perkin–Elmer, MA, USA; λem 420 nm and λex 320 nm)
and 96 wells Perkin Elmer plates, as described previously by Carvalho
and Duzzi et al. [22]. All assays were performed in duplicate, and the
speciﬁc ACE peptidase activities were expressed as units of free ﬂuores-
cence of the cleaved substrates per μg of ACE per min (UF/μg/min). The
peaks with greater inhibition were sent to MS analysis and de novo
sequencing of MS/MS spectra.
2.5. De novo sequencing of peptides by MS/MS
The peptide fractions were automatically injected into a 5 cm C-18
pre-column packed with Jupiter 10 μm resin (Phenomenex; 100 μm
I.D.) using the Easy-nLC II system (Thermo Scientiﬁc). After the loading
process, the peptides were subjected to a chromatographic separation
in a 10 cm C-18 column packed with AQUA 5 μm resin (Phenomenex;
75 μm I.D.) at a constant ﬂow rate of 200 nL/min. The peptides were
separatedwith a gradient of 5–15% B (B: 0.1% formic acid in acetonitrile)
in 10 min; 15–35% B in 30 min; 35–85% B in 5 min; 85–5% B in 2 min
and 5% B in 8 min. The eluate was electro-sprayed at +1.8 kV into an
LTQ Orbitrap Velos (Thermo Scientiﬁc). The MS spectra were acquired
by FTMS analyzer (scan range: 400–2000 m/z) with a resolution of
30,000, and the instrument was operated on Data Dependent Acquisi-
tion (DDA), where the ten most intense ions per scan were selected
for fragmentation by HCD (higher energy collisionally activated
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an ion for a fragmentation event was set to 5000 cps. The dynamic
exclusion time used was 90 s repeating in intervals of 30 s. The MS
and MS/MS spectra were submitted to bioinformatics analyses using
the PEAKS Studio 7.0 software (Bioinformatics Solutions Inc.). De novo
analysiswas performedwith tolerances of 15 ppmand 0.025 Da for pre-
cursor and fragment ions, respectively, without enzyme speciﬁcity.
Pyroglutamic acid at N-terminus, Gln or Glu, and methionine oxidation
were considered as variable modiﬁcations. Peptide sequences were
considered with Average Local Conﬁdence scores ≥ 75%.
2.6. In vitro assays
2.6.1. Inhibition of ACE activity by synthetic PROs using FRET substrate
Somatic ACE (10 ng) activity assays were performed in order to
determine the inhibition constants (Ki), using 2 concentrations of
Abz- FRK(Dnp)P-OH (1 Km and 2 Km values, Km = 4.0 μM) [23] and
5 concentrations of the synthesized PROs (0.4 to 2.0 μM). The ﬂuo-
rimeter and buffer utilized were under the same conditions as de-
scribed (Section 2.4.). The relative hydrolysis ratio was determined
under zero-order kinetics, with b10% of the substrate consumed.
Controls without PROs were also performed. Ki values were calculated
as described [24]. All assays were performed in triplicate.
2.6.2. Inhibition of ACE activity by synthetic PROs using angiotensin I and
bradykinin as substrates
Somatic ACE (50 ng) was incubated in 100 mM Tris, 50 mM NaCl,
10 μM ZnCl2 buffer, pH 7.0, at 37 °C for 60 min with Ang I and BK
(30 μM). The concentrations of the substrates usedwere predetermined
to yield measures of maximum velocities (Vmax) of the reactions (data
not shown). The relative hydrolysis ratio was determined under
zero-order kinetics, with b 10% of the substrate consumed. Controls
without the PROs were also performed. The hydrolysis was analyzed
using reverse-phase HPLC (Prominence, Shimadzu, Japan) as de-
scribed (Section 2.3.). In all cases, elution was followed by the mea-
surement of ultraviolet absorption (214 nm). The peptidase activity
inhibition of ACE was determined using 3 μM of each synthetized
PRO. The speciﬁc activities were expressed in μM of hydrolyzed sub-
strate per μg of ACE per minute (μM/μg/min). All synthetic PROs
(10 μM)were tested as possible ACE (50 ng) substrates by incubation
period of 4 h–24 h. All assays were performed in duplicate and ana-
lyzed with Student's t test.
2.7. In vivo assays
2.7.1. Arterial pressure and heart rate recordings in conscious rats
In order to recordmean arterial pressure (MAP) and heart rate (HR),
one day before the experiments, the rats were anesthetized with keta-
mine (80 mg/kg of body weight) combined with xylazine (7 mg/kg of
body weight), and a polyethylene tubing (PE-10 connected to a PE-
50) was inserted into the abdominal aorta through the femoral artery,
while at the same time, a second polyethylene tubing was inserted
into the femoral vein for drug administration. Arterial and venous cath-
eters were tunneled subcutaneously and exposed on the back of the rat
to allow access to unrestrained freely moving rats. To record pulsatile
arterial pressure, MAP and HR, the arterial catheter was connected to
a Stathan Gould (P23 Db) pressure transducer coupled to a pre-
ampliﬁer (model ETH-200 Bridge Bio Ampliﬁer), that was connected
to a Powerlab computer data acquisition system (Powerlab 16SP,
ADInstruments). Recordings were performed 1 day after the surgery
and began 30 min after the connection of the arterial line to the
pressure transducer. MAP and HR values recorded immediately before,
aswell as those recorded at themaximumpeak of change after i.v. injec-
tions of the synthesized peptides, were used as reference to calculate
the changes in MAP and HR. Each PRO was tested in one group of
animals (n ≥ 4).2.7.2. MAP and HR in conscious rats that received i.v. PRO
Baseline MAP and HR were recorded for 30 min and then rats re-
ceived i.v. injections of saline (n= 43). Ten minutes later, rats received
i.v. injections of the synthetic peptides (15 μg/kg) and the recordings
continued for an additional 30 min. Each PRO was tested in one group
of animals (n ≥ 4).
2.8. Statistical analysis for in vivo assay
Statistical analysis was made with Sigma Stat version 3.0 (Jandel
Corp., Point Richmond, CA, USA). Data is reported as means ± SEM.
Student's paired t test and one‐ or two‐way parametric ANOVA,
followed by the Newman–Keuls multiple comparison test, were used
as appropriate. Signiﬁcance was set at P b 0.05.
3. Results
3.1. Fractionation of the venoms and searching for ACE inhibitors
After HPLC separation of the low molecular mass constituents
(b10 kDa) from all Bitis spp venoms, the collected peaks were screened
with FRET substrate in order to select the best ones (N90% of ACE inhi-
bition) to proceed with MS analysis. Two fractions from BG, BR, BN
and three from BA were sent to MS analysis, as indicated in Fig. 1.
Comparative chromatogram proﬁles (Fig. 1) indicate a correspondence
in BG, BR and BN proﬁles, but a slightly different proﬁle for the BA
peptide pool.
3.2. Identiﬁcation of new peptides from the Bitis venom
De novo sequencing of MS/MS spectra of the selected peaks of Bitis
venoms resulted in over 150 sequences (supplementary Table S1)
with Average Local Conﬁdence (ALC) above 75%, in which almost 20%
of them are proline-rich oligopeptides having two noteworthy charac-
teristics, a pyroglutamic acid residue (bE) in the N-terminus, and the
fact that most of them present the sequence Ile-Pro-Pro at the C-
terminus. Table 1 shows 34 PROs (supplementary spectra S2) contain-
ing 6–12 amino acid residues, from four different venoms, whereas
themajority are unknownmolecules, with exception of bENWPHPQIPP
and bENWPRPQIPP, respectively named as Bj-PRO-10c and Bj-PRO-10b,
both present in the B. jararaca venom [25,26]. Some molecules have a
high similarity with described PROs, i.e. bEYWPRP sequence, only dif-
fering from BPPVb (bEWPRP, [27]) in the addition of a Tyr after the
bE; bENWPRPK sequence found in BN, matched in 90% with that of
Bj-PRO-10e from Bothrops cotiara [28] and 100% with a bradykinin-
potentiating and C-type natriuretic protein (GenBank AFJ49147.1)
from Crotalus adamanteus [29]. The PRO b EWQRPGPEIPP was the only
one found in two species, B. gabonica and B. g. rhinoceros. Certain PROs
sequences presented intraspeciﬁc, bENWPRPKIPP and bENWPRPQIPP
(BN), or interspeciﬁc, bENWPHPQVPP and bENWPHPQIPP (BR and
BG, respectively) similarities. In addition, some PROs from BR and BN,
including bENWPRPKIPP and bENWPRPQIPP, were also found in an
extended form composed by a methionine and a lysine residues (MK)
right after the double proline in C-terminus (supplementary Table S1).
Differently from the others, B. arietans venom presented plenty of
sequences with an arginine or a lysine on the C-terminus and only
two sequences, bEQRPPRPQIPP and bERPPRPQIPP, have the Ile-Pro-
Pro at the C- terminus.
3.3. Inhibition of ACE by PROs using FRET and physiological substrates
In order to study the activity of Bitis PROs in vitro and in vivo, eight of
the 34 identiﬁed molecules of Table 1 were chemically synthesized.
First, the susceptibility of these PROs to ACE hydrolyses was veriﬁed
on reverse phase HPLC using a C-18 column and, as a result, all peptides
remained stable even after overnight incubation (data not shown).
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Table 1
Sequence, ALC, mass over charge (m/z) and charges of PROs present in selected fractions
from Bitis venoms.
The black boxes indicate in which venom the PROs were found.
BA BG BR BN Sequence ALC % m/z z
<EAMQRGPPEIPP 80 652.3245 2
2340.198298<EAPKPR
<EAPKPRKQ 87 468.2747 2
2412.208399<EHYPAPK
<EHYPAPKK 99 317.8400 3
<ELSDPPPK 94 432.7265 2
2446.730881<ELSDPPPR
<ELSDPPSRP 80 490.2459 2
<ENWPCCPPIPP 87 412.1816 3
<ENWPHPQIPPa,b 81 598.7964 2
<ENWPHPQVPPa 81 591.7882 2
<ENWPHPQVPPMK 98 721.3547 2
<ENWPRAPGIPPMK 88 737.8838 2
<ENWPRPGAIPP 85 608.3161 2
2454.740299<ENWPRPK
<ENWPRPKIPPa 82 608.3347 2
<ENWPRPKIPPMKa 96 492.2691 3
<ENWPRPQIPPa,b 75 608.3175 2
<ENWPRPQIPPMKa 93 492.2572 3
<ENWPRQPIPPMK 88 737.8819 2
<ENWQHCEIPP 75 412.1828 3
<EQRPPRPQIPP 75 648.8609 2
<EQSVPPRP 75 446.2413 2
<ERGPPEIPP 85 487.2583 2
2367.208297<ERPPRP
<ERPPRPQIPP 85 584.8328 2
<EWNPHPQIPP 79 598.7962 2
<EWPRPAPGPEIPPMK 99 561.9604 3
<EWQRGPEPIPPMK 78 773.8945 2
<EWQRGPPEIPP 88 644.3274 2
<EWQRPGPEIPMPK 77 516.2654 3
<EWQRPGPEIPPa 89 644.327 2
<EWRPPAPGPEIPPMK 92 567.2904 3
2415.20299<EYWPRP
a
Selected sequences for synthesis.
b
PROs already described in B. jararaca venom.
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ACE using Abz-FRK(Dnp)P-OH as substrate on a ﬂuorimeter were per-
formed. As observed in Table 2, the PROs have a Ki range of 0.20 to
0.83 μM, in which the PRO from B. gabonica (Bj-PRO-10c) presented
the best Ki value (0.20 μM), followed by B. nasicornis PROs, Bn-PRO-
10c and Bj-PRO-10b (0.25 μM and 0.28 μM respectively). In contrast,
peptides with C-terminus –MK extension are poor inhibitors, present-
ing Ki values of over 100 μM.
Enzymatic inhibition assays using Ang I and BK as substrates were
carried out with the aim of investigating the interaction of all eight
PROs with C- and N- domains of ACE. Fig. 2 shows that all PROs were
able to inhibit ACE activity on both substrates in different degrees. The
relative inhibition percentage of BK hydrolysis did not vary signiﬁcantly
among all 8 PROs (19–38%) but, on the other hand, better values of in-
hibition were obtained when using Ang I as substrate on seven of the
eight tested PROs. The exception was for the extended Bn-PRO-10b-
MK, which inhibits BK hydrolysis of around 19% and Ang I hydrolysis
of 11.2%. In fact, as observed in results using the FRET substrate, the
two extended peptides, Bn-PRO-10a-MK and Bn-PRO-10b-MK, have
the lowest relative inhibition percentages when using both Ang I andFig. 1. Comparative HPLC proﬁle of lowmolecular weight constituents from four different Bitis s
nasicornis. Fractions that better inhibited ACE activity was manually collected for MS/MS de nov
by the straight line.BK as substrates. In addition, Bn-PRO-10c, Bj-PRO-10b and Bj-PRO-10c
presented the highest relative inhibition percentage upon Ang I
(74.8%, 64.9% and 60.0% respectively).
3.4. Cardiovascular effects of intravenous PROs on conscious rats
All PROs (15 μg/kg) i.v. tested induced an immediate and transitory
hypotension (Bn-PRO-10a: −18.8 ± 0.3, Bn-PRO-10a-MK: −13.9 ±
0.4, Bj-PRO-10b:−20.9 ± 1.3, Bn-PRO-10b-MK:−20.9 ± 7.0, Bj-PRO-
10c: −18.7 ± 1.2, Br-PRO-10a: −23.3 ± 4.9, Br-PRO-11a: −12.6 ±
1.3 and Bn-PRO-10c: −18.2 ± 3.1 mmHg, vs. saline: −0.1 ±
0.5 mmHg) as demonstrated on Fig. 3A. Six out of eight PROs also in-
creased HR (Bn-PRO-10a: 49.6 ± 1.5, Bj-PRO-10b: 37 ± 9.4, Bj-PRO-
10c: 37.2 ± 5.2, Br-PRO-10a: 85.6 ± 10.2, Br-PRO-11a: 41.6 ± 13.4
and Bn-PRO-10c: 42.5 ± 13.5 bpm, vs. saline:−3.6 ± 1.5 bpm). The
only exceptions were Bn-PRO-10a-MK (31.8 ± 12.8 bpm) and Bn-
PRO-10b-MK (3.6 ± 13.7 bpm) which did not change HR (Fig. 3B).
The baseline levels ofMAP andHRwere similar in all eight experimental
groups tested, 104.05 ± 3.25 and 366.3 ± 20.47, respectively.
4. Discussion
Snakes of the genus Bitis are considered medically important,
causing serious envenoming in sub-Saharan Africa. Despite the
underreporting of accidents, according to the WHO, the most frequent
snakebites are caused by B. arietans, while the accidentswithGaboon vi-
pers are less frequent; both cases are associated with serious or life-
threatening envenoming [2]. Although there are only a few in-depth
studies on envenoming by these snakes, reports of exacerbated hypo-
tension on victims are frequent [3,30,31]. Some studies have associated
the hypotension presented by the victims with massive bleeding in the
bitten limb [32], but deaths have been reported in patients with circula-
tory collapse without appreciable blood loss [30]. Thus, a direct action
of the venom may be responsible for the hypotension induced in the
envenomation by the genus Bitis. Given this scenario, we decided to
seek molecules present in Bitis venoms that could inhibit ACE.
Interestingly, all venoms have pyroglutamyl proline-rich
oligopeptides (PROs), containing 6–13 amino acid residues, and at least
one proline residue at the C-terminus. Some of the PROs presented here
are closely related with sequences already described in the B. jararaca
venom. Despite the similarities, only two PROs from B. nasicornis
and B. gabonica are identical to the molecules known as Bj-PRO-10b
and Bj-PRO-10c, respectively. It is noteworthy that venoms from snakes
of two distant genera would have identical molecules, which has contin-
ued the same for about 50 Ma [33].
Some new PROs sequences found in the venoms from Gaboon
vipers are extended and show the dipeptide Met-Lys at the C-terminus,
e. g., bEWRPPAPGPEIPPMK, bEQWQRGPEPIPPMK, bEQNWPRQPIPPMK,
bEQNWPRPKIPPMK, bEQNWPHPQVPPMK, among others. Previous
studies described the isolation of the cDNAs coding for a PRO precursor
protein in the venom gland (GenBank AY310916) and in the brain of
B. jararaca (GenBank AF171670) [20,34]. These proteins contain seven
tandemly arranged PROs sequences at the N-terminus, and one C-type
natriuretic peptide (CNP) sequence at the C-terminus. Both B. jararaca
PRO precursor domains comprise three unique copies and two pairs of
repeated peptide sequences, all ﬂanked by a highly conserved sequence
of seven amino acid residues [L(T/K)VQQWA], except the twopentapep-
tides bEKWAP [20]. Thus, we suggest that despite the similarity among
sequences of PROs of the B. jararaca and Bitis venoms, precursor mole-
cules probably have striking differences. Extended sequences were not
found in the B. arietans venom and only two entire PROs, bERPPRPQIPP
and bEQRPPRPQIPP, were detected in the analyzed peaks. Manypecies: (BA) Bitis arietans; (BG) Bitis gabonica; (BR) Bitis gabonica rhinoceros; and (BN) Bitis
o sequencing, and are framed in each chromatogram. Acetonitrile gradient is represented
Table 2
Inhibition constants (Ki values) of the synthetic PROs for ACE activity using the FRET
substrate.
Name Sequence Ki (μM)
Bn-PRO-10a bENWPRPKIPP 0.48
Bn-PRO-10a-MK bENWPRPKIPPMK N100
Bj-PRO-10ba bENWPRPQIPP 0.28
Bn-PRO-10b-MK bENWPRPQIPPMK N100
Bj-PRO-10ca bENWPHPQIPP 0.20
Br-PRO-10a bENWPHPQVPP 0.83
Bg-PRO-11a bEWQRPGPEIPP 0.47
Bn-PRO-10c bENWPRPKVPP 0.25
a PROs already described in B. jararaca venom.
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the four venoms studied here were solubilized in the same condi-
tions, we speculate that the B. arietans venoms may contain more
proteolytic enzymes cleaving the PRO precursor from this venom.
Based on the cleavage points, after arginine and lysine residues, it
is probable that serine peptidases in B. arietans venom are responsi-
ble for PROs degradation. Analyzing all PROs together, the set of pep-
tides from Gaboon viper venoms are closely related to each other,
while the sequences from puff adder appear to be different. These
results are in agreement with studies based on cytochrome b
mitochondrial genes [35], NADH subunit 4, 16S and 12S rRNA [33]
which grouped the Gaboon vipers in the subgenera Macrocerastes,
and isolated B. arietans in the subgenera Bitis.
Among various PROs that were sequenced by mass spectrometry,
we decided to synthesize six new sequences along with the two
known Bj-PRO-10b (bENWPRPQIPP) and Bj-PRO-10c (bENWPHPQIPP),
to check their inhibitory potency on ACE activity using the FRET sub-
strate. The synthetic PROs were not hydrolyzed by ACE, including the
two extended sequences (Bn-PRO-10a-MK and Bn-PRO-10b-MK). Six
of them are potent ACE inhibitors, with Ki values between 0.20–
0.83 μM,while the two extended sequences showweakACE inhibitions,Fig. 2. Inhibition of angiotensin-converting enzyme (ACE) by proline-rich oligopeptides (PROs)
(50 ng) were incubated with 3 μM of each PRO for 60 min when Ang I (30 μM) was used as su
percentage of ACE activity inhibition and were obtained using a C-18 column at the reverse-
Student's t test P b 0.05.even after using higher doses of peptides. As previously stated, Bj-PRO-
10b and Bj-PRO-10c are peptides that are already described for the
B. jararaca venom, but only Bj-PRO-10c has had the inhibition constants
determined [19]. Although described nearly 40 years ago [25], only the
present report evaluates the Bj-PRO-10b, both as ACE inhibitor in vitro
and as hypotensive in vivo. The assessment of the relationship between
the primary sequence of PROs and the obtained Ki values is not clear.
For example, with the intention of investigating whether the IPP
tripeptide at the C-terminus is more effective in inhibiting ACE-I than
the VPP sequence, it is noteworthy to compare the PROs Bn-PRO-10a
(bENWPRPKIPP, Ki = 0.48 μM) with the Bn-PRO-10c (bENWPRPKVPP,
Ki=0.25 μM), and the Bj-PRO-10c (bENWPHPQIPP, Ki=0.20 μM)with
theBr-PRO-10a (bENWPHPQVPP, Ki=0.83 μM).However, noﬁnal con-
clusion has been drawn, indicating that the overall PRO sequence is
more important for ACE inhibition than a single amino acid substitution
in the primary structure.
The captopril's Ki for ACE was determined as 0.046 μM [23],
being over 4 times better when compared with the most potent PRO
(Bj-PRO-10c). It is important to note that the PROs Ki valueswere obtain-
ed using a FRET substrate speciﬁcally developed for the ACE assay, and
that the kcat/Km values for the hydrolysis using two full-length ACE
mutants containing only one intact catalytic site (N- or C-domain) were
16.15 (μM.s)−1 and 25.63 (μM.s)−1, respectively [23]. Since this substrate
is cleaved by both domains, preferably by the ACE's C-domain, we decid-
ed to use angiotensin I and bradykinin as substrates to investigate the
selectivity of PROs for the ACE C- or N-domain more deeply.
Our HPLC results indicate that four of the PROs sequences Bj-PRO-
10b, Bj-PRO-10c Br-PRO-10a and Bn-PRO-10c from Bitis venoms were
better inhibitors for the ACE C-domain since these molecules were
better inhibitors for Ang I and for FRET substrate hydrolysis. On the
other hand, inhibitions of bradykinin hydrolysis by PROs showed no
signiﬁcant variations, and these four peptides were less effective when
compared to results using Ang I as substrate. In accordance with the re-
sults obtained with the FRET substrate, the two extended PROs proved
to be weaker inhibitors.from Bitis spp over angiotensin I (Ang I) and bradykinin (BK) hydrolysis. Samples of ACE
bstrate, and for 120 min with substrate BK (30 μM) at 37 °C. The results are expressed as
phase HPLC system. Experiments were made in duplicate. *Signiﬁcant difference, using
Fig. 3. Changes in (A)mean arterial pressure (MAP) and (B) heart rate (HR) produced by i.v. injection of saline or BPP 1–8 (15 μg/kg). The results are represented asmean± SEM.N=4–7
rats/group.
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molecules, targeting the cardiovascular system of rats. All peptides
were able to reduce the mean arterial pressure (MAP) and six of them
resulted in tachycardia in the animals.
Although we obtained a good correlation with the in vitro results
using different substrates (FRET, Ang I and BK), the same did not
occur with the in vivo results. The most signiﬁcant difference was ob-
tained with both PRO extended sequences, which even though they
were not efﬁcient in vitro ACE inhibitors, they resulted in hypotension
in vivo, specially the Bn-PRO-10b-MK sequence, which was capable of
reducing the MAP similarly to other PROs. Interestingly, the extended
PROs were the ones that did not produce a signiﬁcant heart rate (HR)
increase.
Taking into account all the results presented here, we hypothesize
that the ACE is probably not the only target of PROs in vivo. In
fact, it has been shown that Bj-PRO-10c has as its main target the
argininosuccinate synthetase (AsS) in the kidney cytosol of rats [21],
despite being an effective inhibitor of the C-domain of ACE [19]. Another
explanation for the good hypotensive effect of the two extended PROs
in vivo is that the dipeptide at the C-terminus (MK) may have been
removed by other peptidase different from ACE, and that the observed
effects are due to the mature PROs.
It is postulated in the literature that a purely C-site selective inhibitor
would be beneﬁcial as an antihypertensive drug based on twomain as-
pects: i) it would reduce the vasopressor effect of Ang II by inhibiting its
release by the C-domain; and ii) the preserved activity of the N-domain
would reduce the BK accumulation that is likely responsible for the side
effects of theACE inhibitors, such as the bradykinin-mediated angioede-
ma [36]. Although both characteristics are present in some PROs, it is
noteworthy that these toxins have a relevant role for predation, causing
hypotension and facilitating capture of the prey, regardless of the
selectivity for speciﬁc ACE domains.
The results presented here indicate that a class of bioactive peptides,
PROs, most likely contributes to the hypotensive and cardiovascular
effects caused by the Bitis envenoming. However, we cannot rule out
the possibility of other molecules from Bitis venoms acting synergisti-
cally with the PROs, leading the victims to hypotension. For example,
it is kwon that the B. arietans venom presents a kallidin-releasing
kininogenase from plasma kininogen [8] causing vasodilation, which
may be highly potentiated by the ACE inhibitory effect of the PROs. It
is important to say that the PROs precursors described so far present
natriuretic peptides at the N-terminus [37], which provide another
means of achieving hypotension [38]. Since the PROs were selected
through a screening using the ACE, it was not possible to identify C-
type natriuretic peptides (CNP). However, Francischetti and colleagues
[39] described the GLGC sequence (GenBank AY434452) in a tran-
scriptome study with B. gabonica, which is highly conserved as one of
the four residues of the PROs-CNP precursors.Taken together, it seems that the venoms of the genus Bitis can be
considered an arsenal of molecules that leads the victim to hypotensive
shock and that clearly require special attention in cases of envenoming.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbagen.2015.02.005.
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